| Product Code: ETC9949904 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Non Hodgkin Lymphoma Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Non Hodgkin Lymphoma Market - Industry Life Cycle |
3.4 United Kingdom (UK) Non Hodgkin Lymphoma Market - Porter's Five Forces |
3.5 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.7 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United Kingdom (UK) Non Hodgkin Lymphoma Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of non-Hodgkin lymphoma cases in the UK |
4.2.2 Advancements in treatment options and therapies |
4.2.3 Growing awareness and early detection initiatives |
4.3 Market Restraints |
4.3.1 High treatment costs and healthcare expenditure |
4.3.2 Regulatory challenges in drug approvals and reimbursement policies |
5 United Kingdom (UK) Non Hodgkin Lymphoma Market Trends |
6 United Kingdom (UK) Non Hodgkin Lymphoma Market, By Types |
6.1 United Kingdom (UK) Non Hodgkin Lymphoma Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By B-Cell Lymphomas, 2021- 2031F |
6.1.4 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By T-Cell Lymphoma, 2021- 2031F |
6.2 United Kingdom (UK) Non Hodgkin Lymphoma Market, By Treatment Type |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Chemotherapy, 2021- 2031F |
6.2.3 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Targeted Therapy, 2021- 2031F |
6.2.4 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United Kingdom (UK) Non Hodgkin Lymphoma Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3.4 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United Kingdom (UK) Non Hodgkin Lymphoma Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Speciality Centres, 2021- 2031F |
6.4.5 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Others, 2021- 2031F |
6.5 United Kingdom (UK) Non Hodgkin Lymphoma Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.4 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 United Kingdom (UK) Non Hodgkin Lymphoma Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Non Hodgkin Lymphoma Market Export to Major Countries |
7.2 United Kingdom (UK) Non Hodgkin Lymphoma Market Imports from Major Countries |
8 United Kingdom (UK) Non Hodgkin Lymphoma Market Key Performance Indicators |
8.1 Average time to diagnosis for non-Hodgkin lymphoma patients |
8.2 Percentage of patients receiving targeted therapy |
8.3 Survival rates of non-Hodgkin lymphoma patients |
8.4 Adoption rate of novel treatment options |
8.5 Number of clinical trials for non-Hodgkin lymphoma therapies in the UK |
9 United Kingdom (UK) Non Hodgkin Lymphoma Market - Opportunity Assessment |
9.1 United Kingdom (UK) Non Hodgkin Lymphoma Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 United Kingdom (UK) Non Hodgkin Lymphoma Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.3 United Kingdom (UK) Non Hodgkin Lymphoma Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 United Kingdom (UK) Non Hodgkin Lymphoma Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 United Kingdom (UK) Non Hodgkin Lymphoma Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United Kingdom (UK) Non Hodgkin Lymphoma Market - Competitive Landscape |
10.1 United Kingdom (UK) Non Hodgkin Lymphoma Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Non Hodgkin Lymphoma Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here